Trial reportJournal of translational medicine2010
Safety evaluation of allogeneic umbilical cord blood mononuclear cell therapy for degenerative conditions.
Trial report in Journal of translational medicine, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 73 citations in OpenAlex.
- Transplantation of human cord blood mononuclear cells and umbilical cord-derived mesenchymal stem cells in autism.Journal of translational medicine · 2013Trial
- Beneficial effects of non-matched allogeneic cord blood mononuclear cells upon patients with idiopathic osteoporosis.Journal of translational medicine · 2012Trial
- Human umbilical cord blood-derived mononuclear cell transplantation: case series of 30 subjects with hereditary ataxia.Journal of translational medicine · 2011Trial
- A Biosafety Study of Human Umbilical Cord Blood Mononuclear Cells Transduced with Adenoviral Vector Carrying Human Vascular Endothelial Growth Factor cDNA In Vitro.Biomedicines · 2023Article
- Induction of Angiogenesis by Genetically Modified Human Umbilical Cord Blood Mononuclear Cells.International journal of molecular sciences · 2023Article
- Umbilical cord blood stem cells transplantation in a patient with severe progressive supranuclear palsy: a case report.Journal of medical case reports · 2021Article
- Review
- Gene-modified leucoconcentrate for personalizedNeural regeneration research · 2021Article
- Evaluation of Direct and Cell-Mediated Lactoferrin Gene Therapy for the Maxillofacial Area Abscesses in Rats.Pharmaceutics · 2021Article
- Epidural Stimulation Combined with Triple Gene Therapy for Spinal Cord Injury Treatment.International journal of molecular sciences · 2020Article
- Preventive Triple Gene Therapy Reduces the Negative Consequences of Ischemia-Induced Brain Injury after Modelling Stroke in a Rat.International journal of molecular sciences · 2020Article
- Functional beta-cells derived from umbilical cord blood mesenchymal stem cells for curing rats with streptozotocin-induced diabetes mellitus.Singapore medical journal · 2020Article
- Safety and Feasibility of Repeated Intrathecal Allogeneic Bone Marrow-Derived Mesenchymal Stromal Cells in Patients with Neurological Diseases.Stem cells international · 2019Article
- Allogeneic Umbilical Cord Blood Infusion for Adults with Ischemic Stroke: Clinical Outcomes from a Phase I Safety Study.Stem cells translational medicine · 2018Article
- From cord to caudate: characterizing umbilical cord blood stem cells and their paracrine interactions with the injured brain.Pediatric research · 2018Review
- Triple-Gene Therapy for Stroke: A Proof-of-ConceptFrontiers in pharmacology · 2018Article
- Cardioprotective Effects of Wharton Jelly Derived Mesenchymal Stem Cell Transplantation in a Rodent Model of Myocardial Injury.International journal of stem cells · 2017Article
- Mesenchymal stem/stromal cells-a key mediator for regeneration after perinatal morbidity?Molecular and cellular pediatrics · 2016Article
- Feasibility and safety of intrathecal transplantation of autologous bone marrow mesenchymal stem cells in horses.BMC veterinary research · 2015Article
- Safety of Allogeneic Umbilical Cord Blood Stem Cells Therapy in Patients with Severe Cerebral Palsy: A Retrospective Study.Stem cells international · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe current paradigm for cord blood transplantation is that HLA matching and immune suppression are strictly required to prevent graft versus host disease (GVHD). Immunological arguments and historical examples have been made that the use of cord blood for non-hematopoietic activities such as growth factor production, stimulation of angiogenesis, and immune modulation may not require matching or immune suppression.
methods114 patients suffering from non-hematopoietic degenerative conditions were treated with non-matched, allogeneic cord blood. Doses of 1-3 x 10(7) cord blood mononuclear cells per treatment, with 4-5 treatments both intrathecal and intravenously were performed. Adverse events and hematological, immunological, and biochemical parameters were analyzed for safety evaluation.
resultsNo serious adverse effects were reported. Hematological, immunological, and biochemical parameters did not deviate from normal ranges as a result of therapy.
conclusionThe current hematology-based paradigm of need for matching and immune suppression needs to be revisited when cord blood is used for non-hematopoietic regenerative purposes in immune competent recipients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.